The osteoclast: Friend or foe?

Annual Review of Pathology: Mechanisms of Disease

Volumn 3, Issue , 2008, Pages 457-484

  Novack, Deborah V ^a   Teitelbaum, Steven L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arthritis; Bisphosphonate; Bone; Osteopetrosis; Osteoporosis; RANKL

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLONY STIMULATING FACTOR 1; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR NFAT; VITRONECTIN RECEPTOR;

ALBERS SCHOENBERG DISEASE; ARTHRITIS; BONE DENSITY; BONE MASS; BONE METASTASIS; BONE REMODELING; CELL DIFFERENTIATION; CELL LINEAGE; CELL POLARITY; CYTOSKELETON; FRACTURE; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE AND BONES; BONE DISEASES; BONE RESORPTION; FEMALE; HUMANS; OSTEOCLASTS;

EID: 39649091772     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev.pathmechdis.3.121806.151431     Document Type: Review

References (150)

1. Martin TJ, Sims NA. 2005. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med. 11:76-81
2. Pap T, Claus A, Ohtsu S, Hummel KM, Schwartz P, et al. 2003. Osteoclast-independent bone resorption by fibroblast-like cells. Arthritis Res. Ther. 5:R163-73
3. Rasmussen H, Bordier P. 1973. The cellular basis of metabolic bone disease. N. Engl. J. Med. 289:25-32
4. Walker DG. 1973. Osteopetrosis cured by temporary parabiosis. Science 180:275
5. Walker DG. 1975. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science 190:784-85
6. Coccia PF, Krivit W, Cervenka J, Clawson C, Kersey JH, et al. 1980. Successful bone-marrow transplantation for infantile malignant osteopetrosis. N. Engl. J. Med. 302:701-8
7. Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, et al. 1988. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122:1373-82
8. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-19
9. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-76
10. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95:3597-602
11. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, et al. 1999. The ligand for osteoprotegerin (OPGL) direcdy activates mature osteoclasts. J. Cell Biol. 145:527-38
12. Abu-Amer Y, Erdmann J, Alexopoulou L, Kollias G, Ross FP, Teitelbaum SL. 2000. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J. Biol. Chem. 275:27307-10
13. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ. 2002. TNFα potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 143:1108-18
14. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. 2000. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106:1481-88
15. Li J, Sarosi I, Yan X-Q, Morony S, Capparelli C, et al. 2000. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97:1566-71
16. Kanazawa K, Azuma Y, Nakano H, Kudo A. 2003. TRAF5 functions in both RANKL-and TNF α-induced osteoclastogenesis. J. Bone Miner. Res. 18:443-50
17. Kanazawa K, Kudo A. 2005. TRAF2 is essential for TNF-α-induced osteoclastogenesis. J. Bone Miner. Res. 20:840-47
18. Asagiri M, Takayanagi H. 2007. The molecular understanding of osteoclast differentiation. Bone 40:251-64
19. Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, et al. 2004. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J. Clin. Invest. 114:475-84
20. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, et al. 2005. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202:1261-69
21. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, et al. 1994. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266:443-48
22. Koga T, Inui M, Inoue K, Kim S, Suematsu A, et al. 2004. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428:758-63
23. Mocsai A, Humphrey MB, Van Ziffle JA, Hu Y, Burghardt A, et al. 2004. The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc. Natl. Acad. Sci. USA 101:6158-63
24. Mao D, Epple H, Uthgenannt B, Novack DV, Faccio R. 2006. PLCγ2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J. Clin. Invest. 116:2869-79
25. Arron JR, Choi Y. 2000. Bone versus immune system. Nature 408:535-36
26. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. 2005. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 115:282-90
27. Yoshida H, Hayashi S-I, Kunisada T, Ogawa M, Nishikawa S, et al. 1990. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345:442-44
28. Zou W, Kitaura H, Reeve J, Long F, Tybulewicz VLJ, et al. 2007. Syk, c-Src, the αvβ3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J. Cell Biol. 176:877-88
29. Faccio R, Novack DV, Zallone A, Ross FP, Teitelbaum SL. 2003. Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by β3 integrin. J. Cell Biol. 162:499-509
30. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, et al. 2000. Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest. 105:433-40
31. Yarali N, Fisgin T, Duru F, Kara A. 2003. Osteopetrosis and Glanzmann's thrombasthenia in a child. Ann. Hematol. 82:254-56
32. Horton MA, Massey HM, Rosenberg N, Nicholls B, Seligsohn U, Flanagan AM. 2003. Upregulation of osteoclast α2β1 integrin compensates for lack of αvβ3 vitronectin receptor in Iraqi-Jewish-type Glanzmann thrombasthenia. Br. J. Haematol. 122:950-57
33. Zhao H, Kitaura H, Sands MS, Ross FP, Teitelbaum SL, Novack DV. 2005. Critical role of β3 integrin in experimental postmenopausal osteoporosis. J. Bone Miner. Res. 20:2116-23
34. Lane NE, Yao W, Nakamura MC, Humphrey MB, Kimmel D, et al. 2005. Mice lacking the integrin β5 subunit have accelerated osteoclast maturation and increased activity in the estrogen-deficient state. J. Bone Miner. Res. 20:58-66
35. Feng X, Novack DV, Faccio R, Ory DS, Aya K, et al. 2001. A Glanzmann's mutation in β3 integrin specifically impairs osteoclast function. J. Clin. Invest. 107:1137-44
36. Soriano P, Montgomery C, Geske R, Bradley A. 1991. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702
37. Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. 1992. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J. Clin. Invest. 90:1622-27
38. -/- mutant mice. Genes Dev. 11:2835-44
39. Miyazaki T, Sanjay A, Neff L, Tanaka S, Home WC, Baron R. 2004. Src kinase activity is essential for osteoclast function. J. Biol. Chem. 279:17660-66
40. Ridley AJ, Hall A. 1992. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70:389-99
41. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. 1992. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70:401-10
42. Faccio R, Teitelbaum SL, Fujikawa K, Chappel J, Zallone A, et al. 2005. Vav3 regulates osteoclast function and bone mass. Nat. Med. 11:284-90
43. Jurdic P, Saltel F, Chabadel A, Destaing O. 2006. Podosome and sealing zone: specificity of the osteoclast model. Eur. J. Cell Biol. 85:195-202
44. Faccio R, Takeshita S, Colaianni G, Chappel JC, Teitelbaum SL, Ross FP. 2007. M-CSF regulates the cytoskeleton via recruitment of a multimeric signaling complex to c-Fms Y559/697/721. J. Biol. Chem. 282:18991-99
45. Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL. 2003. c-Fms and the αvβ3 integrin collaborate during osteoclast differentiation. J. Clin. Invest. 111:749-58
46. Baron R, Neff L, Louvard D, Courtoy PJ. 1985. Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J. Cell Biol. 101:2210-22
47. Riihonen R, Supuran CT, Parkkila S, Pastorekova S, Vaananen HK, Laitala-Leinonen T. 2007. Membrane-bound carbonic anhydrases in osteoclasts. Bone 40:1021-31
48. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. 1989. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245:855-57
49. Abu-Amer Y, Ross FP, Schlesinger P, Tondravi MM, Teitelbaum SL. 1997. Substrate recognition by osteoclast precursors induces s-crc/microtubule association. J. Cell Biol. 137:247-58
50. Mattsson JP, Schlesinger PH, Keeling DJ, Teitelbaum SL, Stone DK, Xie X-S. 1994. Isolation and reconstitution of a vacuolar-type proton pump of osteoclast membranes. J Biol. Chem. 269:24979-82
51. Lee SH, Rho J, Jeong D, Sul JY, Kim T, et al. 2006. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat. Med. 12:1403-9
52. Teti A, Blair HC, Teitelbaum SL, Kahn AJ, Koziol CM, et al. 1989. Cytoplasmic pH regulation and chloride/bicarbonate exchange in avian osteoclasts. J. Clin. Invest. 83:227-33
53. Schlesinger PH, Blair HC, Teitelbaum SL, Edwards JC. 1997. Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption. J. Biol. Chem. 272:18636-43
54. Henriksen K, Sorensen MG, Nielsen RH, Gram J, Schaller S, et al. 2006. Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification. J. Bone Miner. Res. 21:58-66
55. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, et al. 1998. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA 95:13453-58
56. Mulari MT, Zhao H, Lakkakorpi PT, Vaananen HK. 2003. Osteoclast ruffled border has distinct subdomains for secretion and degraded matrix uptake. Traffic 4:113-25
57. Albers-Schonberg HE. 1904. Rontgenbilder einer seltenen Knockenerkrankung. Munch Med. Wochenschr. 51:365-68
58. Tolar J, Teitelbaum SL, Orchard PJ. 2004. Osteopetrosis. N. Engl. J Med. 351:2839-49
59. Sly WS, Hewett-Emmett D, Whyte MP, Yu Y-S, Tashian RE. 1983. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc. Natl. Acad. Sci. USA 80:2752-56
60. Bollerslev J, Andersen PE Jr. 1989. Fracture patterns in two types of autosomal-dominant osteopetrosis. Acta Orthop. Scand. 60:110-12
61. Cournot G, Trubert-Thil CL, Petrovic M, Boyle A, Cormier, et al. 1992. Mineral metabolism in infants with malignant osteopetrosis: heterogeneity in plasma 1,25-dihydroxyvitamin D levels and bone histology. J. Bone Miner. Res. 7:1-10
62. McMahon C, Will A, Hu P, Shah GN, Sly WS, Smith OP. 2001. Bone marrow transplantation corrects osteopetrosis in the carbonic anhydrase II deficiency syndrome. Blood 97:1947-50
63. Hu PY, Lim EJ, Ciccolella J, Strisciuglio P, Sly WS. 1997. Seven novel mutations in carbonic anhydrase II deficiency syndrome identified by SSCP and direct sequencing analysis. Hum. Mutat. 9:383-87
64. Frattini A, Orchard PJ, Sobacchi C, Giliani S, Abinun M, et al. 2000. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat. Genet. 25:343-46
65. Bruder E, Stallmach T, Peier K, Superti-Furga A, Vezzoni P. 2003. Osteoclast morphology in autosomal recessive malignant osteopetrosis due to a TCIRG1 gene mutation. Pediatr. Pathol. Mol. Med. 22:3-9
66. Sobacchi C, Frattini A, Orchard P, Porras O, Tezcan I, et al. 2001. The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum. Mol. Genet. 10:1767-73
67. Frattini A, Blair HC, Sacco MG, Cerisoli F, Faggioli F, et al. 2005. Rescue of ATPa3-deficient murine malignant osteopetrosis by hematopoietic stem cell transplantation in utero. Proc. Natl. Acad. Sci. USA 102:14629-34
68. Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, et al. 2001. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104:205-15
69. Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, et al. 2001. Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum. Mol. Genet. 10:2861-67
70. Campos-Xavier AB, Saraiva JM, Ribeiro LM, Munnich A, Cormier-Daire V. 2003. Chloride channel 7 (CLCN7) gene mutations in intermediate autosomal recessive osteopetrosis. Hum. Genet. 112:186-89
71. Waguespack SG, Koller DL, White KE, Fishburn T, Cam G, et al. 2003. Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J. Bone Miner. Res. 18:1513-18
72. Benichou OD, Laredo JD, de Vernejoul MC. 2000. Type II autosomal dominant osteopetrosis (Albers-Schonberg disease): clinical and radiological manifestations in 42 patients. Bone 26:87-93
73. el-Tawil T, Stoker DJ. 1993. Benign osteopetrosis: a review of 42 cases showing two different patterns. Skeletal Radiol. 22:587-93
74. Pettersson U, Albagha OM, Mirolo M, Taranta A, Frattini A, et al. 2005. Polymorphisms of the CLCN7 gene are associated with BMD in women. J. Bone Miner. Res. 20:1960-67
75. Fleming KW, Barest G, Sakai O. 2007. Dental and facial bone abnormalities in pyknodysostosis: CT findings. AJNR Am. J. Neuroradiol. 28:132-34
76. Edelson JG, Obad S, Geiger R, On A, Artul HJ. 1992. Pycnodysostosis. Orthopedic aspects with a description of 14 new cases. Clin. Orthop. Relat. Res. Jul.: 263-76
77. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, et al. 2006. Glucocorticoids suppress bone formation via the osteoclast. J. Clin. Invest. 116:2152-60
78. Manolagas SC. 2000. Corticosteroids and fractures: a close encounter of the third cell kind. J. Bone Miner. Res. 15:1001-5
79. Reszka AA, Rodan GA. 2003. Bisphosphonate mechanism of action. Curr. Rheumatol. Rep. 5:65-74
80. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, et al. 2004. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350:1189-99
81. Ott SM. 2001. Fractures after long-term alendronate therapy. J. Clin. Endocrinol. Metab. 86:1835-36
82. Li J, Mashiba T, Burr DB. 2001. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif. Tissue Int. 69:281-86
83. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. 2005. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90:1294-301
84. Armamento-Villareal R, Napoli N, Panwar V, Novack D. 2006. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N. Engl. J. Med. 355:2048-50
85. Compston JE. 2006. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 40:1447-52
86. Finkelstein JS, Leder BZ, Burnett SA, Wyland JJ, Lee H, et al. 2006. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J. Clin. Endocrinol. Metab. 91:2882-87
87. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, et al. 2005. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr. Rev. 26:688-703
88. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. 1996. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 93:5925-30
89. Smith CL, O'Malley BW. 2004. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25:45-71
90. Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, et al. 2003. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J. Clin. Invest. 111:1651-64
91. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, et al. 2002. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298:843-46
92. Kameda T, Mano H, Yuasa T, Mori Y, Miyazawa K, et al. 1997. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J. Exp. Med. 186:489-95
93. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. 1996. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat. Med. 2:1132-36
94. Zhang Y-H, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y. 2001. Tumor necrosis factor-α (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J. Biol. Chem. 276:563-68
95. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Pacifici R. 2000. Estrogen deficiency induces bone loss by enhancing T cell production of TNFα. J. Clin. Invest. 106:1229-37
96. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, et al. 2001. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. USA 98:13960-65
97. Cenci S, Toraldo G, Weitzmann MN, Roggia C., Gao Y, et al. 2003. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-γ-induced class II transactivator. Proc. Natl. Acad. Sci. USA 100:10405-10
98. Grassi F, Pacifici R. 2005. Ovariectomy increases the formation of T cell niches at the resorption surfaces. J. Bone Miner. Res. 20:F395
99. Weitzmann MN, Pacifici R. 2006. Estrogen deficiency and bone loss: an inflammatory tale. J Clin. Invest. 116:1186-94
100. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. 1996. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273:1222-25
101. Toraldo G, Roggia C, Qian W-P, Pacifici R, Weitzmann MN. 2003. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor κB ligand and tumor necrosis factor α from T cells. Proc. Natl. Acad. Sci. USA 100:125-30
102. Ryan MR, Shepherd R, Leavey JK, Gao Y, Grassi F, et al. 2005. An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc. Natl. Acad. Sci. USA 102:16735-40
103. Lee SK, Kalinowski JF, Jacquin C, Adams DJ, Gronowicz G, Lorenzo JA. 2006. Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J. Bone Miner. Res. 21:695-702
104. Lee SK, Kadono Y, Okada F, Jacquin C, Koczon-Jaremko B, et al. 2006. T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. J. Bone Miner. Res. 21:1704-12
105. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, et al. 2006. FSH directly regulates bone mass. Cell 125:247-60
106. Iqbal J, Sun L, Kumar TR, Blair HC, Zaidi M. 2006. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc. Natl. Acad. Sci. USA 103:14925-30
107. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. 2004. Androgens and bone. Endocr. Rev. 25:389-425
108. Rochira V, Balestrieri A, Madeo B, Zirilli L, Granata AR, Carani C. 2006. Osteoporosis and male age-related hypogonadism: role of sex steroids on bone (patho)physiology. Eur. J. Endocrinol. 154:175-85
109. Greenspan SL, Greenspan FS. 1999. The effect of thyroid hormone on skeletal integrity. Ann. Intern. Med. 130:750-58
110. Britto JM, Fenton AJ, Holloway WR, Nicholson GC. 1994. Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 134:169-76
111. Gothe S, Wang Z, Ng L, Kindblom JM, Barros AC, et al. 1999. Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. Genes Dev. 13:1329-41
112. Abe E, Marians RC, Yu W, Wu XB, Ando T, et al. 2003. TSH is a negative regulator of skeletal remodeling. Cell 115:151-62
113. Goldring SR, Gravallese EM. 2002. Pathogenesis of bone lesions in rheumatoid arthritis. Curr. Rheumatol. Rep. 4:226-31
114. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. 2001. Osteoprotegerin and receptor activator of nuclear factor κB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 40:623-30
115. Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, et al. 2002. Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann. Rheum. Dis. 61:1047-54
116. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, et al. 1999. Activated T cells regulate bone loss and joint destraction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-9
117. Hirayama T, Danks L, Sabokbar A, Athanasou NA. 2002. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. Rheumatology (Oxford) 41:1232-39
118. Pettit A, Ji H, von Stechow D, Muller R, Goldring S, et al. 2001. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J Pathol. 159:1689-99
119. Hayden MS, Ghosh S. 2004. Signaling to NF-κB. Genes Dev. 18:2195-224
120. Clohisy JC, Roy BC, Biondo C, Frazier E, Willis D, et al. 2003. Direct inhibition of NF-κB blocks bone erosion associated with inflammatory arthritis. J. Immunol. 171:5547-53
121. Dai S, Hirayama T, Abbas S, Abu-Amer Y. 2 004. The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J. Biol. Chem. 279:37219-22
122. Jimi E, Aoki K, Saito H, D'Acquisto F, May JJ, et al. 2004. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 10:617-24
123. Aya K, Alhawagri M, Hagen-Stapleton A, Kitaura H, Kanagawa O, Veis Novack D. 2005. NF-κB-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J. Clin. Invest. 115:1848-54
124. Findlay DM, Haynes DR. 2005. Mechanisms of bone loss in rheumatoid arthritis. Mod. Rheumatol. 15:232-40
125. Nakano K, Okada Y, Saito K, Tanikawa R, Sawamukai N, et al. 2006. Rheumatoid synovial endothelial cells produce macrophage colony-stimulating factor leading to osteoclastogenesis in rheumatoid arthritis. Rheumatology 46:597-603
126. Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, Teitelbaum SL. 2005. M-CSF mediates TNF-induced inflammatory osteolysis. J. Clin. Invest. 115:3418-27
127. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. 2006. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J. Rheumatol. 33:2398-108
128. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, et al. 2004. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 50:277-90
129. Mundy GR. 2002. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2:584-93
130. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, et al. 2006. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res. 12(Pt. 2):6213s-16s
131. Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, et al. 2003. Platelet and osteoclast β3 integrins are critical for bone metastasis. Proc. Natl. Acad. Sci. USA 100:14205-10
132. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. 2001. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 61:4432-36
133. Gao L, Deng H, Zhao H, Hirbe A, Harding J, et al. 2005. HTLV-1 tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood 106:4294-302
134. Body JJ. 2001. Bisphosphonates in the treatment of metastatic breast cancer. J. Mammary Gland Biol. Neoplasia 6:477-85
135. Lipton A, Berenson JR, Body J-J, Boyce BF, Bruland OS, et al. 2006. Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clin. Cancer Res. 12:6209s-12s
136. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, et al. 1999. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103:197-206
137. Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, et al. 2002. Transforming growth factor-β stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J. Biol. Chem. 277:24571-78
138. Brown JE, Cook RJ, Major P, Lipton A, Saad F, et al. 2005. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl. Cancer Inst. 97:59-69
139. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, et al. 2005. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 23:4925-35
140. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. 2002. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J. Urol. 168:1005-7
141. Roodman GD. 2004. Mechanisms of bone metastasis. N. Engl. J. Med. 350:1655-64
142. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, et al. 2001. Osteoprotegerin inhibits the development of osteolytic bone disease in mulitple myeloma. Blood 98:3534-40
143. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, et al. 2003. The role of the wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349:2483-94
144. Roodman GD, Windle JJ. 2005. Paget disease of bone. J. Clin. Invest. 115:200-8
145. Morales-Piga AA, Rey-Rey JS, Corres-Gonzalez J, Garcia-Sagredo JM, Lopez-Abente G. 1995. Frequency and characteristics of familial aggregation of Paget's disease of bone. J. Bone Miner. Res. 10:663-70
146. Laurin N, Brown JP, Morissette J, Raymond V. 2002. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am. J. Hum. Genet. 70:1582-88
147. Kurihara N, Hiruma Y, Zhou H, Subler MA, Dempster DW, et al. 2007. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J. Clin. Invest. 117:133-12
148. Singer FR. 1999. Update on the viral etiology of Paget's disease of bone. J. Bone Miner. Res. 14(Suppl. 2):29-33
149. Kurihara N, Reddy SV, Menaa C, Anderson D, Roodman GD. 2000. Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J. Clin. Invest. 105:607-14
150. Kurihara N, Zhou H, Reddy SV, Garcia Palacios V, Subler MA, et al. 2006. Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice. J. Bone Miner. Res. 21:446-55